Literature DB >> 15984412

The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib.

Tasuku Mashiba1, Satoshi Mori, David B Burr, Satoshi Komatsubara, Yongping Cao, Takeshi Manabe, Hiromichi Norimatsu.   

Abstract

We evaluated the effects of suppressed bone remodeling caused by bisphosphonate on microdamage accumulation and degree of mineralization of bone (DMB) for the dog rib in two independent studies. Study 1: 36 female beagles, 1-2 years old, were treated daily for 1 year with saline vehicle, risedronate at 0.5 mg/kg/day, or alendronate at 1.0 mg/kg/day. Study 2: 29 beagles, 1 year old, were given lactose, or incadronate at 0.3 mg/kg/day or 0.6 mg/kg/day for 3 years. In both studies, the ninth rib was harvested. Intracortical remodeling was significantly suppressed following either 1 year or 3 years of bisphosphonate treatment without impairment of primary mineralization, although the remodeling rate was obviously lower in study 2 than in study 1 because of the aging of animals. Microdamage accumulation was significantly increased following any bisphosphonate treatment in response to the extent of remodeling suppression. One-year treatment with risedronate or alendronate did not significantly affect the mean DMB or osteonal distribution based on DMB. In contrast, mean DMB was significantly increased following 3 years of incadronate treatments, and osteonal distributions based on DMB showed a dose-dependent shift toward the higher values in incadronate-treated animals when compared with controls. Our results demonstrated that DMB was increased following only 3 years but not 1 year of bisphosphonate treatment. This finding suggests that suppressed remodeling induced by long-term bisphosphonate treatment increased DMB by increasing the population of old, highly mineralized osteons; however, the expression of this phenomenon depends on duration of the treatment because the secondary mineralization is a very slow process.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15984412     DOI: 10.1007/BF03026321

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  24 in total

1.  Validity of the bulk-staining technique to separate artifactual from in vivo bone microdamage.

Authors:  D B Burr; T Stafford
Journal:  Clin Orthop Relat Res       Date:  1990-11       Impact factor: 4.176

2.  Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.

Authors:  A M Parfitt; M K Drezner; F H Glorieux; J A Kanis; H Malluche; P J Meunier; S M Ott; R R Recker
Journal:  J Bone Miner Res       Date:  1987-12       Impact factor: 6.741

3.  Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties.

Authors:  M C Monier-Faugere; Z Geng; E P Paschalis; Q Qi; I Arnala; F Bauss; A L Boskey; H H Malluche
Journal:  J Bone Miner Res       Date:  1999-10       Impact factor: 6.741

4.  Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

Authors:  T Mashiba; T Hirano; C H Turner; M R Forwood; C C Johnston; D B Burr
Journal:  J Bone Miner Res       Date:  2000-04       Impact factor: 6.741

5.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors:  S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal:  JAMA       Date:  1999-10-13       Impact factor: 56.272

6.  Trabecular bone volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures.

Authors:  S Mori; R Harruff; W Ambrosius; D B Burr
Journal:  Bone       Date:  1997-12       Impact factor: 4.398

7.  Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women.

Authors:  G Y Boivin; P M Chavassieux; A C Santora; J Yates; P J Meunier
Journal:  Bone       Date:  2000-11       Impact factor: 4.398

8.  Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups.

Authors:  D B Karpf; D R Shapiro; E Seeman; K E Ensrud; C C Johnston; S Adami; S T Harris; A C Santora; L J Hirsch; L Oppenheimer; D Thompson
Journal:  JAMA       Date:  1997-04-09       Impact factor: 56.272

9.  Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra.

Authors:  Satoshi Komatsubara; Satoshi Mori; Tasuku Mashiba; Masako Ito; Jiliang Li; Yoshio Kaji; Tomoyuki Akiyama; Kensaku Miyamoto; Yongping Cao; Jun Kawanishi; Hiromichi Norimatsu
Journal:  J Bone Miner Res       Date:  2003-03       Impact factor: 6.741

10.  In vivo trabecular microcracks in human vertebral bone.

Authors:  T E Wenzel; M B Schaffler; D P Fyhrie
Journal:  Bone       Date:  1996-08       Impact factor: 4.398

View more
  42 in total

1.  Bisphosphonate-associated femur fractures have high complication rates with operative fixation.

Authors:  Mark L Prasarn; Jaimo Ahn; David L Helfet; Joseph M Lane; Dean G Lorich
Journal:  Clin Orthop Relat Res       Date:  2012-06-06       Impact factor: 4.176

2.  Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects.

Authors:  Crystal K Tjhia; Clarita V Odvina; D Sudhaker Rao; Susan M Stover; Xiang Wang; David P Fyhrie
Journal:  Bone       Date:  2011-09-18       Impact factor: 4.398

Review 3.  Subtrochanteric femoral insufficiency fractures related to the use of long-term bisphosphonates: a pictorial review.

Authors:  Nanda Venkatanarasimha; Gemma Miles; Priya Suresh
Journal:  Emerg Radiol       Date:  2010-07-20

4.  Bisphosphonates inhibit cell functions of HUVECs, fibroblasts and osteogenic cells via inhibition of protein geranylgeranylation.

Authors:  Nadine Hagelauer; Thomas Ziebart; Andreas M Pabst; Christian Walter
Journal:  Clin Oral Investig       Date:  2014-09-27       Impact factor: 3.573

5.  Factors Associated with Increased Healing Time in Complete Femoral Fractures After Long-Term Bisphosphonate Therapy.

Authors:  Hae-Seong Lim; Chong-Kwan Kim; Youn-Soo Park; Young-Wan Moon; Seung-Jae Lim; Sang-Min Kim
Journal:  J Bone Joint Surg Am       Date:  2016-12-07       Impact factor: 5.284

6.  Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.

Authors:  Jeanny B Aragon-Ching; Yang-Min Ning; Clara C Chen; Lea Latham; Jean-Pierre Guadagnini; James L Gulley; Philip M Arlen; John J Wright; Howard Parnes; William D Figg; William L Dahut
Journal:  Cancer Invest       Date:  2009-02       Impact factor: 2.176

7.  Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells.

Authors:  C Walter; M O Klein; A Pabst; B Al-Nawas; H Duschner; T Ziebart
Journal:  Clin Oral Investig       Date:  2009-03-18       Impact factor: 3.573

Review 8.  Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.

Authors:  Beatrice J Edwards; Andrew D Bunta; Joseph Lane; Clarita Odvina; D Sudhaker Rao; Dennis W Raisch; June M McKoy; Imran Omar; Steven M Belknap; Vishvas Garg; Allison J Hahr; Athena T Samaras; Matthew J Fisher; Dennis P West; Craig B Langman; Paula H Stern
Journal:  J Bone Joint Surg Am       Date:  2013-02-20       Impact factor: 5.284

9.  Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study.

Authors:  Takafumi Majima; Akira Shimatsu; Yasato Komatsu; Noriko Satoh; Atsushi Fukao; Kiyoshi Ninomiya; Tadashi Matsumura; Kazuwa Nakao
Journal:  J Bone Miner Metab       Date:  2009-01-28       Impact factor: 2.626

10.  Theoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage.

Authors:  Xiang Wang; Antonia M Erickson; Matthew R Allen; David B Burr; R Bruce Martin; Scott J Hazelwood
Journal:  J Biomech       Date:  2009-03-12       Impact factor: 2.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.